Liquid biopsy-based biomarkers for the characterization of hormone receptor-positive (HR+) HER2-Low metastatic breast cancer (mBC)

被引：0
|
作者：
Bortot, L. [1 ]
Basile, D. [2 ]
Palmero, L. [1 ]
Dri, A. [1 ]
Cucciniello, L. [1 ]
Buriolla, S. [1 ]
Pasto, B. [1 ]
Mazzeo, R. [1 ]
Bonotto, M. [3 ]
Bolzonello, S. [4 ]
Franzoni, A. [5 ]
Allegri, L. [5 ]
Belletti, B. [6 ]
Damante, G. [1 ]
Gerratana, L. [7 ]
Minisini, A. M. M. [3 ]
Puglisi, F. [8 ,9 ]
机构：
[1] Univ Udine, Dept Med DAME, Udine, Italy
[2] San Giovanni Dio Hosp, Med Oncol Unit, Crotone, Italy
[3] Azienda Sanitaria Univ Friuli Cent ASUFC, Santa Maria Misericordia Acad Hosp, Dept Oncol, Udine, Italy
[4] Ctr Riferimento Oncologico CRO, Dept Med Oncol, IRCCS, Aviano, Italy
[5] Azienda Sanitaria Univ Friuli Centrale ASUFC, Inst Human Genet, Udine, Italy
[6] Ctr Riferimento Oncol Aviano CRO, Mol Oncol Unit, IRCCS, Aviano, Italy
[7] Ctr Riferimento Oncol CRO, Dept Med Oncol, IRCCS, Aviano, Italy
[8] Univ Udine, Dept Med DAME, Udine, Italy
[9] Univ Udine, Dept Med DAME, Pordenone, Italy
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.300
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
261P
引用
收藏
页码：S656 / S657
页数：2
相关论文
共 50 条
  • [1] A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2-metastatic breast cancer (MBC).
    Wander, Seth Andrew
    Zangardi, Mark
    Niemierko, Andrzej
    Kambadakone, Avinash
    Kim, Leslie S. L.
    Xi, Jing
    Pandey, Apurva Kumari
    Spring, Laura
    Stein, Casey
    Juric, Dejan
    Kuter, Irene
    Moy, Beverly
    Mulvey, Therese Marie
    Vidula, Neelima
    Isakoff, Steven J.
    Yuen, Megan
    Brufsky, Adam
    Ma, Cynthia X.
    O'Shaughnessy, Joyce
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [3] The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer
    Tajiri, Wakako
    Nakamura, Yoshiaki
    Kawasaki, Junji
    Koi, Yumiko
    Akiyoshi, Sayuri
    Koga, Chinami
    Tokunaga, Eriko
    CANCER RESEARCH, 2024, 84 (09)
  • [4] registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Tripathy, D.
    Kaufman, P.
    Brufsky, A.
    Mayer, M.
    Yood, M.
    Wang, L.
    Brammer, M.
    Yardley, D.
    Tan-Chiu, E.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Hormone receptor-positive HER2-low metastatic breast cancer (mBC): evolution of HER2 status after CDK4/6 inhibitor treatment
    de Nonneville, Alexandre
    Finetti, Pascal
    Boudin, Laurys
    Usclade, Lucas
    Mescam, Lenaig
    Durieux, Emeline
    Boucraut, Agathe
    Viret, Frederic
    Mamessier, Emilie
    Goncalves, Anthony
    Bertucci, Francois
    CANCER RESEARCH, 2024, 84 (09)
  • [6] Prognostic value and relapse pattern of HER2-low in hormone receptor-positive breast cancer
    Wei, Tong
    Kang, Yikun
    Wang, Xue
    Yue, Jian
    Xu, Binghe
    Yuan, Peng
    THORACIC CANCER, 2024, 15 (07) : 550 - 558
  • [7] The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer
    Park, Woong Ki
    Nam, Seok Jin
    Kim, Seok Won
    Lee, Jeong Eon
    Yu, Jonghan
    Ryu, Jai Min
    Chae, Byung Joo
    CANCERS, 2023, 15 (22)
  • [8] Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2-mBC): Prevalence, biomarker characteristics, and outcomes.
    Jeselsohn, Rinath
    Chen, Lu
    Chaudhary, Nayan
    Martinalbo, Jorge
    Fasching, Peter A.
    Hafner, Marc
    Luhn, Patricia
    Montero, Alberto J.
    Perez-Moreno, Pablo Diego
    Wander, Seth Andrew
    Kalinsky, Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Patterns of care and patient characteristics in postmenopausal women with HER2+and hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Sharma, P. P.
    Sail, K.
    Delea, T. E.
    Forsyth, M. T.
    Halm, M.
    Nagarwala, Y. M.
    Lopez, W.
    Patt, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Exploring the interplay between tumor burden and liquid biopsy longitudinal evaluation in hormone receptor-positive, HER2-negative metastatic breast cancer (MBC)
    Mazzeo, R.
    Bortot, L.
    Michelotti, A.
    Buriolla, S.
    Palmero, L.
    Franzoni, A.
    Bertoli, E.
    Targato, G.
    Allegri, L.
    Da Ros, L.
    Alberti, M.
    Di Nardo, P.
    Bonotto, M.
    Sodde, S.
    Belletti, B.
    Spazzapan, S.
    Baldassarre, G.
    Damante, G.
    Gerratana, L.
    Puglisi, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S492 - S493
12345